Fluvoxamine and chlorimipramine in endogenous depression
Thirty patients were treated in a randomised double-blind efficacy study of fluvoxamine and chlorimipramine. The dose range for both drugs was 50-300 mg in divided daily doses. Mean daily doses were higher for fluvoxamine than chlorimipramine. Generally the baseline recordings were comparable for both drug groups. Fluvoxamine was superior to chlorimipramine in all the rating scales used without achieving statistical significance. Chlorimipramine, but not fluvoxamine, caused a significant decrease in blood pressure. There were no significant effects on ECG or laboratory variables. There was no significant relationship between plasma levels of either compound or metabolite and clinical response. Chlorimipramine exerted more unwanted effects than fluvoxamine. Autonomic effects of fluvoxamine were minimal in comparison with chlorimipramine. Chlorimipramine patients required more concurrent anxiolytic medication than fluvoxamine. Both drug groups required a significant amount of concurrent hypnotic medication.
Fluvoxamine-a new serotonin re-uptake inhibitor: first clinical and psychometric experiences in depressed patients
Ion-pair liquid chromatography of steady-state plasma levels of chlorimipramine and demethylchlorimipramine
Inhibition of synaptosomal high-affinity uptake of dopamine and serotonin by estrogen agonists and antagonists
Do recent efficacy data on the drug treatment of acute bipolar depression support the position that drugs other than antidepressants are the treatment of choice? A conceptual review
Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects
Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability
Sertraline versus fluvoxamine in the treatment of elderly patients with major depression: a double-blind, randomized trial
Concentration-response relationship for fluvoxamine using remission as an endpoint: a receiver operating characteristics curve analysis in major depression
Antidepressant-associated mood-switching and transition from unipolar major depression to bipolar disorder: a review
Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients
The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants
Fluvoxamine by itself has potential to directly induce long QT syndrome at supra-therapeutic concentrations
WITHDRAWN: Selective serotonin reuptake inhibitors (SSRIs) versus other antidepressants for depression
A case with occurring adverse effects when cross-over titration from fluvoxamine to paroxetine associated with increasing the plasma fluvoxamine level in major depressive disorder
Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity
Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors?
Cardiac effects of antidepressant drugs. A comparison of the tricyclic antidepressants and fluvoxamine
Treatment strategy in depression. I. Non-tricyclic and selective reuptake inhibitors in resistant depression: a double-blind partial crossover study on the effects of oxaprotiline and fluvoxamine
Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions
Determination of fluvoxamine in human plasma by high-performance liquid chromatography with ultraviolet detection
Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.